OBJECTIVE: To identify patients with GFPT1-related limb-girdle myasthenia and analyze phenotypic consequences of the mutations. METHODS: We performed genetic analysis, histochemical, immunoblot, and ultrastructural studies and in vitro electrophysiologic analysis of neuromuscular transmission. RESULTS: We identified 16 recessive mutations in GFPT1 in 11 patients, of which 12 are novel. Ten patients had slowly progressive limb-girdle weakness responsive to cholinergic agonists with onset between infancy and age 19 years. One patient (no. 6) harbored a nonsense mutation and a second mutation that disrupts the muscle-specific GFPT1 exon. This patient never moved in utero, was apneic and arthrogrypotic at birth, and was bedfast, tube-fed, and barely responded to therapy at age 6 years. Histochemical studies in 9 of 11 patients showed tubular aggregates in 6 and rimmed vacuoles in 3. Microelectrode studies of intercostal muscle endplates in 5 patients indicated reduced synaptic response to acetylcholine in 3 and severely reduced quantal release in patient 6. Endplate acetylcholine receptor content was moderately reduced in only one patient. The synaptic contacts were small and single or grape-like, and quantitative electron microscopy revealed hypoplastic endplate regions. Numerous muscle fibers of patient 6 contained myriad dilated and degenerate vesicular profiles, autophagic vacuoles, and bizarre apoptotic nuclei. Glycoprotein expression in muscle was absent in patient 6 and reduced in 5 others. CONCLUSIONS: GFPT1-myasthenia is more heterogeneous than previously reported. Different parameters of neuromuscular transmission are variably affected. When disruption of muscle-specific isoform determines the phenotype, this has devastating clinical, pathologic, and biochemical consequences.
OBJECTIVE: To identify patients with GFPT1-related limb-girdle myasthenia and analyze phenotypic consequences of the mutations. METHODS: We performed genetic analysis, histochemical, immunoblot, and ultrastructural studies and in vitro electrophysiologic analysis of neuromuscular transmission. RESULTS: We identified 16 recessive mutations in GFPT1 in 11 patients, of which 12 are novel. Ten patients had slowly progressive limb-girdle weakness responsive to cholinergic agonists with onset between infancy and age 19 years. One patient (no. 6) harbored a nonsense mutation and a second mutation that disrupts the muscle-specific GFPT1 exon. This patient never moved in utero, was apneic and arthrogrypotic at birth, and was bedfast, tube-fed, and barely responded to therapy at age 6 years. Histochemical studies in 9 of 11 patients showed tubular aggregates in 6 and rimmed vacuoles in 3. Microelectrode studies of intercostal muscle endplates in 5 patients indicated reduced synaptic response to acetylcholine in 3 and severely reduced quantal release in patient 6. Endplate acetylcholine receptor content was moderately reduced in only one patient. The synaptic contacts were small and single or grape-like, and quantitative electron microscopy revealed hypoplastic endplate regions. Numerous muscle fibers of patient 6 contained myriad dilated and degenerate vesicular profiles, autophagic vacuoles, and bizarre apoptotic nuclei. Glycoprotein expression in muscle was absent in patient 6 and reduced in 5 others. CONCLUSIONS:GFPT1-myasthenia is more heterogeneous than previously reported. Different parameters of neuromuscular transmission are variably affected. When disruption of muscle-specific isoform determines the phenotype, this has devastating clinical, pathologic, and biochemical consequences.
Authors: Andre Maues De Paula; Marc Bartoli; Sebastien Courrier; Jean Pouget; Nicolas Levy; Jean-François Pellissier; Dominique Figarella-Branger; Martin Krahn; Shahram Attarian Journal: Muscle Nerve Date: 2012-12 Impact factor: 3.217
Authors: A G Engel; E H Lambert; D M Mulder; C F Torres; K Sahashi; T E Bertorini; J N Whitaker Journal: Ann Neurol Date: 1982-06 Impact factor: 10.422
Authors: Jan Senderek; Juliane S Müller; Marina Dusl; Tim M Strom; Velina Guergueltcheva; Irmgard Diepolder; Steven H Laval; Susan Maxwell; Judy Cossins; Sabine Krause; Nuria Muelas; Juan J Vilchez; Jaume Colomer; Cecilia Jimenez Mallebrera; Andres Nascimento; Shahriar Nafissi; Ariana Kariminejad; Yalda Nilipour; Bita Bozorgmehr; Hossein Najmabadi; Carmelo Rodolico; Jörn P Sieb; Ortrud K Steinlein; Beate Schlotter; Benedikt Schoser; Janbernd Kirschner; Ralf Herrmann; Thomas Voit; Anders Oldfors; Christopher Lindbergh; Andoni Urtizberea; Maja von der Hagen; Angela Hübner; Jacqueline Palace; Kate Bushby; Volker Straub; David Beeson; Angela Abicht; Hanns Lochmüller Journal: Am J Hum Genet Date: 2011-02-11 Impact factor: 11.025
Authors: Duygu Selcen; Xin-Ming Shen; Joan Brengman; Ying Li; Anthony A Stans; Eric Wieben; Andrew G Engel Journal: Neurology Date: 2014-04-23 Impact factor: 9.910
Authors: Adi Aran; Reeval Segel; Kota Kaneshige; Suleyman Gulsuner; Paul Renbaum; Scott Oliphant; Tomer Meirson; Ariella Weinberg-Shukron; Yair Hershkovitz; Sharon Zeligson; Ming K Lee; Abraham O Samson; Stanley M Parsons; Mary-Claire King; Ephrat Levy-Lahad; Tom Walsh Journal: Neurology Date: 2017-02-10 Impact factor: 9.910